ReviewNature reviews. Nephrology2014
Management of hyperkalaemia in chronic kidney disease.
Review in Nature reviews. Nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Comparative effects of salt substitutes on blood pressure, cardiovascular events and mortality: a systematic review and network meta-analysis.BMC medicine · 2026Pooled it
- Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.European heart journal · 2018Pooled it
- A nomogram to predict hyperkalemia in patients with hemodialysis: a retrospective cohort study.BMC nephrology · 2022Trial
- Trial
- Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.Clinical journal of the American Society of Nephrology : CJASN · 2015Trial
- Life-Threatening Ventricular Tachycardia and Transient Brugada-Like Electrocardiographic Abnormalities Caused by Severe Hyperkalemia Due to Urinary Retention in a 55-Year-Old Man.The American journal of case reports · 2026Article
- Article
- Patient and Clinician Perspectives on Hyperkalemia Management Under Cardio-Kidney-Protective Therapy: A Three-Stakeholder Cross-Sectional Survey.Electrolyte & blood pressure : E & BP · 2026Article
- [Current primary care management of patients with hyperkalemia in Germany - Findings on monitoring, diagnosis, and treatment of elevated potassium levels].Deutsche medizinische Wochenschrift (1946) · 2026Article
- Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions.Kidney research and clinical practice · 2026Article
- Article
- Impact of RAAS blockers on serum potassium and mortality in a large dialysis cohort: a longitudinal analysis.Clinical kidney journal · 2026Article
- From Biomarkers to Biosensors: Transforming Comorbidity Management in Dialysis Care.Sensors (Basel, Switzerland) · 2026Review
- Correction to: Hyperkalemia in heart failure with reduced ejection fraction: implications and management.Heart failure reviews · 2026Article
- What to do with key cardiovascular drugs when kidney function worsens?Clinical kidney journal · 2026Review
- Elevated Fatty Acid Binding Protein 4 (FABP4) Associated With Liver Damage and Kidney Complications in Thalassemia Patients.BioMed research international · 2026Article
- Impact of COVID-19 on Renal Function: Analysis of Acute Kidney Injury Across Three Pandemic Waves.Biomedicines · 2025Article
- Hyperkalemia in Clinical Practice, an Important Reminder of Testing Modality.Clinical case reports · 2025Article
- Article
- Sinus arrest consequence of moderate hyperkalemia: a case report.Oxford medical case reports · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Hyperkalaemia is common in patients with chronic kidney disease (CKD), in part because of the effects of kidney dysfunction on potassium homeostasis and in part because of the cluster of comorbidities (and their associated treatments) that occur in patients with CKD. Owing to its electrophysiological effects, severe hyperkalaemia represents a medical emergency that usually requires prompt intervention, whereas the prevention of hazardous hyperkalaemic episodes in at-risk patients requires measures aimed at the long-term normalization of potassium homeostasis. The options for effective and safe medical interventions to restore chronic potassium balance are few, and long-term management of hyperkalaemia is primarily limited to the correction of modifiable exacerbating factors. This situation can result in a difficult trade-off in patients with CKD, because drugs that are beneficial to these patients (for example, renin-angiotensin-aldosterone-system antagonists) are often the most prominent cause of their hyperkalaemia. Maintaining the use of these beneficial medications while implementing various strategies to control potassium balance is desirable; however, discontinuation rates remain high. The emergence of new medications that specifically target hyperkalaemia could lead to a therapeutic paradigm shift, emphasizing preventive management over ad hoc treatment of incidentally discovered elevations in serum potassium levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.